Global Familial Amyloid Polyneuropathy Therapeutic Market Growth (Status and Outlook) 2023-2029

Global Familial Amyloid Polyneuropathy Therapeutic Market Growth (Status and Outlook) 2023-2029

Familial Amyloid Polyneuropathy (FAP) is a progressive, disabling and life-threatening polyneuropathy affecting the peripheral and autonomic nervous system. FAP is an autosomal transmission disorder which is usually due to a point mutation of the transthyretin (TTR) gene.The treatment of familial amyloid polyneuropathies (FAP) is complex and requires a neurological and cardiological multidisciplinary coverage. It includes specific treatments to control the progression of the systemic amyloidogenesis, the symptomatic treatment of the peripheral and autonomic neuropathy (digestive, urinary, sexual, postural hypotension) and the treatment of organs severely involved by amyloidosis (heart, eyes, kidneys).

LPI (LP Information)' newest research report, the “Familial Amyloid Polyneuropathy Therapeutic Industry Forecast” looks at past sales and reviews total world Familial Amyloid Polyneuropathy Therapeutic sales in 2022, providing a comprehensive analysis by region and market sector of projected Familial Amyloid Polyneuropathy Therapeutic sales for 2023 through 2029. With Familial Amyloid Polyneuropathy Therapeutic sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Familial Amyloid Polyneuropathy Therapeutic industry.

This Insight Report provides a comprehensive analysis of the global Familial Amyloid Polyneuropathy Therapeutic landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Familial Amyloid Polyneuropathy Therapeutic portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Familial Amyloid Polyneuropathy Therapeutic market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Familial Amyloid Polyneuropathy Therapeutic and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Familial Amyloid Polyneuropathy Therapeutic.

The global Familial Amyloid Polyneuropathy Therapeutic market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for Familial Amyloid Polyneuropathy Therapeutic is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key Familial Amyloid Polyneuropathy Therapeutic players cover Pfizer Inc., Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Corino Therapeutics Inc., Proclara Biosciences and Arcturus Therapeutics Inc, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of Familial Amyloid Polyneuropathy Therapeutic market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Inotersen
Tafamidis
Patisiran
Others

Segmentation by application
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Pfizer Inc.
Alnylam Pharmaceuticals Inc.
Ionis Pharmaceuticals Inc.
Corino Therapeutics Inc.
Proclara Biosciences
Arcturus Therapeutics Inc

Please note: The report will take approximately 2 business days to prepare and deliver.